Related Experiment Video
Updated: Jan 30, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Evolving concepts in the pathogenesis of uraemic cardiomyopathy
Xiaoliang Wang1, Joseph I Shapiro2
1Joan C. Edwards School of Medicine, Marshall University, Huntington, WV, USA.
Insights
Uraemic cardiomyopathy, cardiac issues in chronic kidney disease (CKD), involves diastolic dysfunction and left ventricular hypertrophy. Understanding its complex causes, including FGF23 and inflammation, is key to improving patient outcomes.
Area of Science:
- Nephrology
- Cardiology
- Pathophysiology
Background:
- Uraemic cardiomyopathy describes cardiac abnormalities in chronic kidney disease (CKD) patients.
- Historically, it was a severe condition reversible by renal transplantation.
- Currently, it's characterized by diastolic dysfunction, left ventricular hypertrophy, and fibrosis in CKD.
Purpose of the Study:
- To review evolving concepts in uraemic cardiomyopathy pathogenesis.
- To explore the roles of FGF23, inflammation, and oxidant stress.
- To examine interactions with established mechanisms like pressure/volume overload and neurohormonal activation.
Main Methods:
- Literature review focusing on recent advancements.
- Analysis of established and emerging pathogenic factors.
- Synthesis of information on FGF23, inflammation, oxidant stress, mineral metabolism, and cardiotonic steroids.
Main Results:
- Uraemic cardiomyopathy is multifactorial, involving both traditional and novel pathways.
- Fibroblast growth factor 23 (FGF23), inflammation, and oxidant stress play significant roles.
- Established factors include pressure/volume overload, renin-angiotensin system activation, and abnormal mineral metabolism.
Conclusions:
- Current treatments for uraemic cardiomyopathy offer modest improvements.
- Further research into novel pathways like FGF23 is crucial for therapeutic development.
- A comprehensive understanding of uraemic cardiomyopathy's complex etiology is needed to improve CKD patient cardiac outcomes.
Abstract:
The term uraemic cardiomyopathy refers to the cardiac abnormalities that are seen in patients with chronic kidney disease (CKD). Historically, this term was used to describe a severe cardiomyopathy that was associated with end-stage renal disease and characterized by severe functional abnormalities that could be reversed following renal transplantation. In a modern context, uraemic cardiomyopathy describes the clinical phenotype of cardiac disease that accompanies CKD and is perhaps best characterized as diastolic dysfunction seen in conjunction with left ventricular hypertrophy and fibrosis. A multitude of factors may contribute to the pathogenesis of uraemic cardiomyopathy, and current treatments only modestly improve outcomes. In this Review, we focus on evolving concepts regarding the roles of fibroblast growth factor 23 (FGF23), inflammation and systemic oxidant stress and their interactions with more established mechanisms such as pressure and volume overload resulting from hypertension and anaemia, respectively, activation of the renin-angiotensin and sympathetic nervous systems, activation of the transforming growth factor-β (TGFβ) pathway, abnormal mineral metabolism and increased levels of endogenous cardiotonic steroids.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Self-Concept
Infancy and Emerging Recognition
During infancy, self-concept is virtually nonexistent. Babies do not distinguish themselves as separate entities and often mistake their...
Cardiomyopathy V: Interprofessional Care
Concepts and Prototypes
The brain organizes this information using concepts, which are mental categories grouping linguistic data,...

